Green Park & Golf Ventures

Green Park & Golf Ventures LLC is a venture capital firm established in 2011 and headquartered in Dallas, Texas, with an additional office in Houston. The firm focuses on early-stage and seed-stage investments, primarily in the healthcare technology, SaaS, and consumer health sectors. With over 50 years of combined operational and financial expertise among its leadership, Green Park & Golf Ventures aims to provide strategic solutions and financial backing to its portfolio companies. The firm typically invests between $0.1 million and $1 million and is particularly interested in opportunities within the North Texas area. Led by Clay Heighten, M.D., and Carl Soderstrom, the firm leverages their extensive experience in healthcare management to identify and support promising startups in the medical-related fields.

Clay Heighten

Founding Member

John Leader

Principal, Investment Operations

Daniel Parsley

Managing Partner

Garcia, J. R.

Partner

Past deals in Texas

MicroTransponder

Series E in 2022
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.

Alto

Series B in 2021
Alto provides on-demand rides using a dedicated fleet of new, safe, and well-maintained vehicles. Each driver is an employee of Alto and is carefully vetted and trained to give members a professional and predictable ride, every time. Alto's elegant apps and in-car technology customize each member's experience each time. In short, members drive everything, except for the car. The company is launching in Dallas, Texas with plans to scale to new US cities in 2019. Alto was founded in 2018 and is headquartered in Dallas, Texas, United States

Avanta Risk Management

Seed Round in 2021
Avanta Risk Management offers financial management and consulting services. Data procurement, validation, and risk mitigation strategies exist within the financial services industry, ranging from nonexistent to more formal models. For inquiries, email, telephone numbers, and physical addresses are available on their website.

Noninvasix

Venture Round in 2021
Noninvasix, Inc. (the “Company” or “Noninvasix”) is a medical technology company that has developed a novel solution to non-invasively monitor for the first time, oxygen sufficiency in organs and veins. The Company was founded in 2007 by Dr. Donald Prough and Dr. Rinat Esenaliev at the University of Texas Medical Branch (UTMB) and is based out of Houston, Texas. The Company has raised over $6.8 million to date including a seed round in Q4 2021. The platform technology of the Company has been developed with $6 million in grants from the NIH and DOD. The Company has also been a part of prestigious accelerator programs such as Philips Healthworks, TMCx, JLabs, Health Wildcatters and has won multiple awards for their innovation. The non-invasive technology has been clinically validated in multiple peer-reviewed journals. The IP portfolio of the Company includes 9 U.S. and 8 global patents.

Worlds

Series A in 2020
Worlds, Inc. specializes in spatial artificial intelligence solutions, offering its flagship platform, SpatialSense. This innovative platform integrates deep learning and Internet of Things (IoT) technology within a four-dimensional environment, allowing organizations to remotely observe and analyze their physical spaces. Key components of SpatialSense include WorldTrainer, which trains the AI to recognize people, objects, and events; WorldBuilder, which facilitates the importation and calibration of 3D models for detailed analysis; WorldNavigator, enabling virtual navigation between locations; and WorldAI, which helps clients create specialized AI applications and virtual entities. The company targets various sectors, including military, healthcare, and energy, to enhance operational insights and efficiency. Founded in 2018, Worlds, Inc. is headquartered in Dallas, Texas.

OneDay

Series A in 2019
OneDay is a Texas-based software-as-a-service company that focuses on enhancing business growth and customer engagement through video storytelling technology. The company's online application provides tools for businesses to create customizable branded video content at scale. It includes question-and-answer prompts specifically designed for senior living communities, aiming to boost resident engagement and enhance customer satisfaction. By leveraging its platform, OneDay enables clients to utilize effective video marketing strategies, ultimately driving revenue growth and improving overall customer experiences.

Ataia

Seed Round in 2018
Ataia Medical, founded in 2017 by a team of biomedical engineers and critical care physicians, is dedicated to empowering patients with the freedom to speak. They develop novel solutions to help patients communicate who are currently unable to because of hard plastic hospital masks.

CounterFind

Seed Round in 2017
CounterFind Inc., based in Dallas, Texas, specializes in software that tracks and eliminates advertisements for counterfeit products in real-time. Founded in 2016, the company utilizes a proprietary filtering formula combined with advanced image recognition technology and industry expertise to identify and remove counterfeit merchandise listings on platforms like Facebook and Amazon. This turnkey solution assists brands in protecting their intellectual property by effectively detecting and shutting down infringing advertisements and product listings online.

Take Command

Seed Round in 2017
Take Command Health is an innovative health insurance software provider for small businesses and independent professionals. Take Command Health enables small employers to reimburse employees tax-free for health insurance using a small business HRA (QSEHRA). The company empowers employees and independent professionals to make smart health insurance decisions using our innovative plan choice software and health management tools.

Meta SaaS

Seed Round in 2017
Meta SaaS is the best SaaS management tool for small & medium businesses. Manage SaaS vendors, reduce SaaS spend, and manage cloud applications from a single and easy to use dashboard.

Ortho Kinematics

Venture Round in 2017
Ortho Kinematics is a spine diagnostics company, provides spine motion analysis and diagnostic services. The company provides information to spine clinicians to assist them in diagnosing and treating back and neck pain. Its solution includes KineGraph Vertebral Motion Analyzer, an automated functional diagnostic test for the spine that uses fluoroscopy to capture the spine in motion, producing patient-specific graphs of the kinematics for each vertebral level. The company was founded in 2006 and is based in Austin, Texas.

Orb Health

Series A in 2016
Orb Health, Inc. is a mobile healthcare technology company based in Richardson, Texas, founded in 2011. It specializes in providing innovative solutions that facilitate access to personalized healthcare services for physicians, employers, clinical laboratories, and patients. The company’s flagship offering, Collaborative Virtual Care, allows healthcare providers to deliver reimbursed Medicare services, including Chronic Care Management, as a virtual extension of their practice. This model eliminates the need for additional staff, applications, or office space, integrating seamlessly with existing electronic medical records (EMR) systems. By embedding best practices into its workflow, Orb Health empowers remote providers to deliver high-quality care while enhancing collaboration among healthcare teams. This approach not only improves patient access and outcomes but also increases reimbursements and overall profitability for various healthcare organizations, including Federally Qualified Health Centers and Accountable Care Organizations.

Archeio Technologies

Seed Round in 2016
Archeio Technologies provides a robust application suite for exploration and production companies to leverage across multiple web and mobile platforms to streamline the collection and management of data for petroleum engineers, geologists, land, and regulatory to make better business decisions.

Take Command

Seed Round in 2016
Take Command Health is an innovative health insurance software provider for small businesses and independent professionals. Take Command Health enables small employers to reimburse employees tax-free for health insurance using a small business HRA (QSEHRA). The company empowers employees and independent professionals to make smart health insurance decisions using our innovative plan choice software and health management tools.

Dignitana

Venture Round in 2016
Dignitana AB is a medical technology company that specializes in scalp cooling technology to assist cancer patients undergoing chemotherapy. The company has developed the DigniCap® Scalp Cooling System, a patented device designed to minimize chemotherapy-induced hair loss. Clinical studies have shown that the system is effective, with over 80% of treated patients able to retain enough hair to avoid the need for a wig. Dignitana's focus is on enhancing the well-being and quality of life of patients during their treatment journey, and it generates a significant portion of its revenue from the United States market.

Adient Medical

Series C in 2016
Adient Medical Inc. is a company specializing in the development and delivery of implantable and absorbable medical devices, primarily focused on preventing pulmonary embolisms. Founded in 2012 and headquartered in Pearland, Texas, Adient Medical aims to create devices that are safe and effective throughout their intended use, and then naturally dissolve without the need for surgical removal. This innovative approach not only enhances patient safety but also reduces the potential for complications and the costs associated with removal procedures. Through its absorbable vascular filter, Adient Medical provides healthcare professionals with a safer alternative for managing the risk of pulmonary embolism in patients.

Savara Pharmaceuticals

Series C in 2016
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Xclaim Mobile

Convertible Note in 2016
Xclaim Mobile, Inc. is a company that specializes in developing an enterprise-grade mobile offer platform aimed at enhancing digital marketing efforts. Founded in 2016 and based in Dallas, Texas, Xclaim offers a platform that streamlines the transition to mobile marketing by integrating location-based technology. This software detects user devices, locations, and wallet types, allowing for customized offers compatible with major mobile payment systems such as Apple Pay, Android Pay, and Microsoft Wallet. By enabling marketers to deliver targeted content through mobile wallets, Xclaim helps brands engage consumers effectively based on time and location triggers. The platform serves various industries, including telecommunications, consumer lending, automotive, and retail, facilitating improved customer interaction and driving revenue through enhanced digital advertising strategies.

MicroTransponder

Series C in 2015
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.

Supergoop

Series A in 2015
Supergoop is a skincare brand completely dedicated to sun protection.

CancerGene Connect

Seed Round in 2015
CancerGene Connect is a developer of a cloud-based genetic assessment platform that focuses on collecting, assessing, and managing genetic family histories. The platform enhances genetic counseling programs by streamlining the collection of family medical histories and facilitating cancer risk assessments. This innovative approach allows clinicians to dedicate more time to addressing patient risks, as it significantly reduces the time spent on organizing data. By leveraging evolving technology, CancerGene Connect aims to create powerful connections between patients and healthcare providers, ultimately improving the overall effectiveness of cancer risk management.

Kickbox

Seed Round in 2015
Kickbox ensures you only send email to real users and helps you separate the low-quality addresses from high-value contacts. Protect your reputation, increase open rates, and save money with Kickbox.

Dignitana

Venture Round in 2015
Dignitana AB is a medical technology company that specializes in scalp cooling technology to assist cancer patients undergoing chemotherapy. The company has developed the DigniCap® Scalp Cooling System, a patented device designed to minimize chemotherapy-induced hair loss. Clinical studies have shown that the system is effective, with over 80% of treated patients able to retain enough hair to avoid the need for a wig. Dignitana's focus is on enhancing the well-being and quality of life of patients during their treatment journey, and it generates a significant portion of its revenue from the United States market.

Admittance Technologies

Series A in 2015
Admittance Technologies is committed to improving the quality of life of patients with heart disease through innovative electrical engineering solutions. Admittance will accomplish this goal through the application of CardioVol™, which can interrogate the heart with electric fields, and in real-time distinguish the blood and heart muscle components of these fields. They focus on the blood signal to warn patients of impending heart failure, maximize their hearts’ ejection of blood by properly tuning the pacing of these weakened hearts, and using stroke volume to determine if VT and rapid afib are hemodynamically unstable requiring defibrillation.

Orb Health

Seed Round in 2015
Orb Health, Inc. is a mobile healthcare technology company based in Richardson, Texas, founded in 2011. It specializes in providing innovative solutions that facilitate access to personalized healthcare services for physicians, employers, clinical laboratories, and patients. The company’s flagship offering, Collaborative Virtual Care, allows healthcare providers to deliver reimbursed Medicare services, including Chronic Care Management, as a virtual extension of their practice. This model eliminates the need for additional staff, applications, or office space, integrating seamlessly with existing electronic medical records (EMR) systems. By embedding best practices into its workflow, Orb Health empowers remote providers to deliver high-quality care while enhancing collaboration among healthcare teams. This approach not only improves patient access and outcomes but also increases reimbursements and overall profitability for various healthcare organizations, including Federally Qualified Health Centers and Accountable Care Organizations.

Vapogenix

Series B in 2015
Vapogenix is a clinical-stage company developing a new class of non-narcotic analgesics for localized pain. It focuses on treating pain locally at its source their products are formulated volatile anesthetics currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. It was founded in 2006 and headquartered in Houston, Texas.

Lantern Pharma

Funding Round in 2015
Lantern Pharma Inc. is a clinical stage biotechnology company based in Dallas, Texas, specializing in precision oncology therapeutics. The company employs artificial intelligence and machine learning to develop innovative cancer treatments and to revitalize abandoned drug candidates. Its lead drug candidate, LP-100, is currently undergoing phase II clinical trials for metastatic, castration-resistant prostate cancer. Additionally, Lantern is developing LP-300 as a combination therapy for female non-smokers diagnosed with non-small cell lung cancer adenocarcinoma. The firm is also advancing LP-184, a preclinical drug candidate designed to target cancer cells that overexpress specific biomarkers. Lantern Pharma utilizes its proprietary RADR platform to address challenges in oncology drug development, such as patient stratification and understanding mechanisms of action, thereby aiming to accelerate the development of personalized cancer therapies.

Ikonopedia

Series B in 2014
Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Ikonopedia provides patient letters and a questionnaire in 9 languages and runs on all modern devices and systems including tablets. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

Socrates Health Solutions

Series A in 2014
Socrates Health Solutions improves access to affordable care via the application of technology and delivery models. They are currently engaged in Series A activities. Socrates Health Solutions is headquartered in Dallas, Texas, and is a Delaware based corporation.

AdBm Technologies

Series A in 2014
AdBm Technologies is an acoustical engineering company that specializes in developing high-performance, low-cost, and easy-to-deploy noise abatement technology for marine environments. The company focuses on the fields of environmental engineering, marine technology, and mechanical engineering. It was founded in 2012 and headquartered in Austin, Texas.

Savara Pharmaceuticals

Series C in 2014
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Cariloop

Seed Round in 2014
Cariloop, Inc. offers a digital platform designed to assist seniors and their families in navigating geriatric care options. The platform connects users with a variety of services, including assisted living facilities, Alzheimer care, adult daycare, hospice care, skilled nursing facilities, and home health care. It enables care providers to showcase their services through real-time updates, multimedia content, and analytics on user engagement. Additionally, Cariloop provides a team of experienced Care Coaches who offer personalized guidance to families throughout their caregiving journey. By combining these resources, Cariloop aims to alleviate caregiver stress, enhance collaboration among care teams, and facilitate better care management for seniors. Founded in 2012 and headquartered in Dallas, Texas, Cariloop serves as a comprehensive support system for families facing the complexities of elder care.

Ortho Kinematics

Venture Round in 2014
Ortho Kinematics is a spine diagnostics company, provides spine motion analysis and diagnostic services. The company provides information to spine clinicians to assist them in diagnosing and treating back and neck pain. Its solution includes KineGraph Vertebral Motion Analyzer, an automated functional diagnostic test for the spine that uses fluoroscopy to capture the spine in motion, producing patient-specific graphs of the kinematics for each vertebral level. The company was founded in 2006 and is based in Austin, Texas.

ImageVision

Series B in 2014
ImageVision specializes in providing advanced image and video recognition solutions for social media and multimedia platforms. By utilizing artificial intelligence and machine learning, the company automates the recognition and monetization of visual content, thereby enhancing revenue opportunities and safeguarding brand integrity for its clients. Their real-time visual recognition technology is employed by major industry players to facilitate image search, brand analytics, and ad customization, while also effectively managing objectionable content. ImageVision's platform includes features for automated filtering, motion recognition, and facial biometrics, enabling clients to operate more efficiently and reduce risks associated with content management.

Tractus

Series A in 2014
TRACTUS addresses the specific need in the healthcare marketplace for a low-cost software and hardware platform for whole breast ultrasound. The combined system uses a unique accessory probe that clips onto standard ultrasound systems and then integrates with a proprietary software suite for reviewing and reporting the whole breast ultrasound scan. Its primary device is the BreastMapper and potentially doubles the discovery of small, treatable breast cancers often missed in dense-breasted women. It was founded in 2012 and is based in Austin, Texas.

Vapogenix

Series B in 2013
Vapogenix is a clinical-stage company developing a new class of non-narcotic analgesics for localized pain. It focuses on treating pain locally at its source their products are formulated volatile anesthetics currently unformulated volatile anesthetics are used only as general anesthetics, by inhalation. It was founded in 2006 and headquartered in Houston, Texas.

Socrates Health Solutions

Series A in 2013
Socrates Health Solutions improves access to affordable care via the application of technology and delivery models. They are currently engaged in Series A activities. Socrates Health Solutions is headquartered in Dallas, Texas, and is a Delaware based corporation.

Tractus

Series A in 2013
TRACTUS addresses the specific need in the healthcare marketplace for a low-cost software and hardware platform for whole breast ultrasound. The combined system uses a unique accessory probe that clips onto standard ultrasound systems and then integrates with a proprietary software suite for reviewing and reporting the whole breast ultrasound scan. Its primary device is the BreastMapper and potentially doubles the discovery of small, treatable breast cancers often missed in dense-breasted women. It was founded in 2012 and is based in Austin, Texas.

Brainspace

Series C in 2013
Brainspace Corporation is a pioneer and recognized leader in helping enterprise clients derive meaning, gain insights and identify human connections in unstructured data. Their unique solutions utilize their patented Brainspace platform and are leading the industry in text analytics, accelerating institutional learning and reinventing how organizations exchange knowledge and expertise. Their customers include the Fortune 500, leading consulting firms, legal service providers, and government agencies. Brainspace was founded in 2005 and is headquartered in Addison, TX, USA.

MicroTransponder

Venture Round in 2013
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.

Supergoop

Series A in 2013
Supergoop is a skincare brand completely dedicated to sun protection.

Ikonopedia

Series A in 2013
Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Ikonopedia provides patient letters and a questionnaire in 9 languages and runs on all modern devices and systems including tablets. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

SendInc

Seed Round in 2013
Sendinc provides a simple way to integrate secure email into your own web and software applications. Sendinc helps your organization achieve and maintain compliance with the growing number of regulations including HIPAA,GLBA, SOX, and PCI-DSS.

MicroTransponder

Venture Round in 2013
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.

Tractus

Seed Round in 2013
TRACTUS addresses the specific need in the healthcare marketplace for a low-cost software and hardware platform for whole breast ultrasound. The combined system uses a unique accessory probe that clips onto standard ultrasound systems and then integrates with a proprietary software suite for reviewing and reporting the whole breast ultrasound scan. Its primary device is the BreastMapper and potentially doubles the discovery of small, treatable breast cancers often missed in dense-breasted women. It was founded in 2012 and is based in Austin, Texas.

Perio Sciences

Venture Round in 2012
Perio Sciences, LLC develops oral healthcare products. It offers dental gels, mouth rinse products, toothpastes, and oral care systems. The company sells and distributes its products through dental professionals, hygienists, specialists, other medical professionals, and medi-spas, as well as online. Perio Sciences, LLC was founded in 2008 and is based in Dallas, Texas.

TangoTab

Series A in 2012
TangoTab, Inc. operates a mobile application that connects consumers with restaurants while addressing local hunger in the United States. The app allows users to find nearby restaurants and access exclusive deals by checking in or redeeming offers at participating locations. Each time a deal is utilized, TangoTab donates the cost of a meal to a local food bank, effectively feeding individuals in need. This initiative not only benefits consumers with free restaurant deals but also serves as a yield-management tool for restaurants, helping them increase traffic during slower periods. Incorporated in 2010 and based in Dallas, Texas, TangoTab fosters a community-oriented approach where both consumers and restaurants contribute to combating hunger in their local areas.

MobileLutions

Seed Round in 2012
MobileLutions has developed an easy to use application that disables texting while driving in a moving vehicle. MobileLutions solution requires no hardware installation and can be easily downloaded onto most PDAs, including IPhones and Androids. At least 1.6 million crashes each year or 28% of all traffic crashes involve drivers using cell phones and texting (National Safety Council Jan 2011). Three out of five, or 60% of all drivers with cell phones, use them while driving even though 91% of them know it is unsafe to do so (Harris Interactive July 2011).

EdgePoint Power

Seed Round in 2012
Demand Response programs are becoming an integral component of the evolving smart grid infrastructure. Large commercial building owners and operators are beginning to realize new sources of revenue available for their willingness to shed energy load during periods of peak consumption. Tenant comfort remains a primary concern for owners and operators; however, EdgePoint minimizes those concerns by providing a robust solution that ensures compliance with demand response events while maintaining comfort levels.

Savara Pharmaceuticals

Series B in 2012
Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

MicroTransponder

Series B in 2012
MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases with a focus on vagus nerve stimulation (VNS). Its first commercial product, Vivistim, is FDA approved for ischemic stroke survivors with moderate to severe upper limb impairment six months or more after their stroke.

SendInc

Seed Round in 2012
Sendinc provides a simple way to integrate secure email into your own web and software applications. Sendinc helps your organization achieve and maintain compliance with the growing number of regulations including HIPAA,GLBA, SOX, and PCI-DSS.

Hie Electronics

Series A in 2012
Hie Electronics specializes in the development and implementation of dense, Blu-ray multi-tiered optical data storage units and enterprise-class digital video recorders. Their flagship product, the TeraStack Solution, supplies innovative data backup and disaster recovery capabilities, video surveillance file storage, medical data retention, architectural and engineering database file storage, high-speed paper scanning and image processing, and critical e-mail backup and recovery for small, medium, and large enterprises using Blu-ray optical technology.

DxUpClose

Seed Round in 2012
DxUpClose, Inc. is young company developing a point-of-care bacterial diagnostic that will perform an antibiotic sensitivity test in sixty minutes. The product is designed to screen for specific bacteria, regardless if the sample has the targeted bacteria, it will count the bacteria that are there and perform antibiotic sensitivity tests - all within sixty minutes. At the end of the test, the product will securely send a list of effective antibiotics to the Healthcare worker’s email or smartphone, so results can be rapidly interpreted by a physician who can then either write a prescription or ePrescribe the appropriate antibiotic. This will reduce the delay in optimal patient care present today by one to three days. Their device is designed to weigh less than sixteen ounces, fit in a pocket, run on batteries and survive temperature extremes, making it easy to transport while still retaining its diagnostic reliability.

Ortho Kinematics

Series B in 2011
Ortho Kinematics is a spine diagnostics company, provides spine motion analysis and diagnostic services. The company provides information to spine clinicians to assist them in diagnosing and treating back and neck pain. Its solution includes KineGraph Vertebral Motion Analyzer, an automated functional diagnostic test for the spine that uses fluoroscopy to capture the spine in motion, producing patient-specific graphs of the kinematics for each vertebral level. The company was founded in 2006 and is based in Austin, Texas.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.